{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:37:59Z","timestamp":1779165479352,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Chimerix"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.antiviral.2017.04.002","type":"journal-article","created":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T08:19:21Z","timestamp":1491553161000},"page":"278-286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Efficacy of delayed brincidofovir treatment against a lethal rabbitpox virus challenge in New Zealand White rabbits"],"prefix":"10.1016","volume":"143","author":[{"given":"Irma M.","family":"Grossi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott A.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melicia R.","family":"Gainey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert T.","family":"Krile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Brundage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jody M.","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2017.04.002_bib1","doi-asserted-by":"crossref","first-page":"11084","DOI":"10.1128\/JVI.00423-07","article-title":"Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox","volume":"81","author":"Adams","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2017.04.002_bib2","series-title":"Smallpox Vaccination: Information for Health Care Providers","author":"Centers for Disease Control and Prevention","year":"2016"},{"key":"10.1016\/j.antiviral.2017.04.002_bib3","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1177\/0300985810378649","article-title":"Animal models of orthopoxvirus infection","volume":"47","author":"Chapman","year":"2010","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.antiviral.2017.04.002_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2017.01.009","article-title":"Short-term clinical safety profile of brincidofovir: a favorable benefit\u2013risk proposition in the treatment of smallpox","author":"Chittick","year":"2017","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2017.04.002_bib4","series-title":"Smallpox and its Eradication","author":"Fenner","year":"1988"},{"key":"10.1016\/j.antiviral.2017.04.002_bib5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1086\/375825","article-title":"Smallpox vaccination: a review, part II. Adverse events","volume":"37","author":"Fulginiti","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2017.04.002_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3390\/v8070203","article-title":"Ectromelia virus disease characterization in the BALB\/c mouse: a surrogate model for assessment of smallpox medical countermeasures","volume":"8","author":"Garver","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2017.04.002_bib7","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/rmv.361","article-title":"Studies in smallpox and vaccination. 1913","volume":"12","author":"Hanna","year":"2002","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2017.04.002_bib8","first-page":"002","article-title":"Smallpox: New perspectives regarding risk assessment & management","volume":"S4","author":"Hansen","year":"2012","journal-title":"J.\u00a0Bioterror Biodef."},{"key":"10.1016\/j.antiviral.2017.04.002_bib9","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1001\/jama.281.22.2127","article-title":"Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense","volume":"281","author":"Henderson","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.antiviral.2017.04.002_bib10","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.3390\/v2102213","article-title":"Synthesis and early development of hexadecyloxypropylcidofovir: an oral antipoxvirus nucleoside phosphonate","volume":"2","author":"Hostetler","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2017.04.002_bib11","first-page":"84","article-title":"Expected adverse events in a mass smallpox vaccination campaign","volume":"5","author":"Kemper","year":"2002","journal-title":"Eff. Clin. Pract."},{"key":"10.1016\/j.antiviral.2017.04.002_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1099\/vir.0.026237-0","article-title":"Rabbitpox: a model of airborne transmission of smallpox","volume":"92","author":"Nalca","year":"2011","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.antiviral.2017.04.002_bib12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.antiviral.2014.08.003","article-title":"Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus","volume":"111","author":"Parker","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.04.002_bib13","series-title":"Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases","article-title":"Orthopoxviruses: vaccinia (smallpox vaccine), variola (smallpox), monkeypox, and cowpox","author":"Peterson","year":"2014"},{"key":"10.1016\/j.antiviral.2017.04.002_bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/v3020063","article-title":"Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans","volume":"3","author":"Rice","year":"2011","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2017.04.002_bib15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/v3010047","article-title":"Efficacy of CMX001 as a post exposure antiviral in New Zealand White rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans","volume":"3","author":"Rice","year":"2011","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2017.04.002_bib16","series-title":"ACAM2000, (Smallpox (Vaccinia) Vaccine, Live) Prescribing Information","author":"Sanofi Pasteur","year":"2016"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.antiviral.2017.04.002_bib17","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.1086\/524751","article-title":"US civilian smallpox preparedness and response program, 2003","volume":"46","author":"Strikas","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2017.04.002_bib18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.antiviral.2015.02.007","article-title":"The efficacy and pharmacokinetics of brincidofovir for the treatment of lethal rabbitpox virus infection: a model of smallpox disease","volume":"117","author":"Trost","year":"2015","journal-title":"Antivir. Res."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421630715X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421630715X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T18:25:50Z","timestamp":1535912750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016635421630715X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":20,"alternative-id":["S016635421630715X"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.04.002","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of delayed brincidofovir treatment against a lethal rabbitpox virus challenge in New Zealand White rabbits","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}